Prosecution Insights
Last updated: July 17, 2026
Application No. 18/363,238

STENT

Final Rejection §103
Filed
Aug 01, 2023
Priority
Mar 23, 2021 — continuation of PCTJP2021011857
Examiner
HU, ANN M
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Japan Lifeline Co. Ltd.
OA Round
2 (Final)
68%
Grant Probability
Favorable
3-4
OA Rounds
9m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
637 granted / 941 resolved
-2.3% vs TC avg
Strong +21% interview lift
Without
With
+21.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
48 currently pending
Career history
1000
Total Applications
across all art units

Statute-Specific Performance

§101
0.1%
-39.9% vs TC avg
§103
85.6%
+45.6% vs TC avg
§102
11.0%
-29.0% vs TC avg
§112
1.5%
-38.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 941 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments, with respect to Sirhan teaching the claimed axial force value in Newtons, have been fully considered and are persuasive. However, the Applicant’s remaining arguments regarding the optimization of the axial and the radial forces have been considered, but they are not persuasive. The applicant has not provided any evidence to support the assertion that one of ordinary skill in the art would not modify the axial force of the primary reference to have the claimed value. Objective evidence which must be factually supported by an appropriate affidavit or declaration to be of probative value includes evidence of unexpected results, commercial success, solution of a long-felt need, inoperability of the prior art, invention before the date of the reference, and allegations that the author(s) of the prior art derived the disclosed subject matter from the inventor or at least one joint inventor. See, for example, In re De Blauwe, 736 F.2d 699, 705, 222 USPQ 191, 196 (Fed. Cir. 1984). The arguments of counsel cannot take the place of evidence in the record. In re Schulze, 346 F.2d 600, 602, 145 USPQ 716, 718 (CCPA 1965). Sirhan teaches that it is well known in the art that the structural features of a stent are modified or controlled in order to provide the stent with the desired mechanical characteristics needed to best suit the implantation site (paras. 0050-0060, 0074, 0112-0114, 0193-0199, 0253-0256). Grandfield also recites using different methods of stent construction to modify the values of the axial force in order to provide the stent with the desired mechanical characteristics (para. 0157). It is maintained that it would be obvious to one having ordinary skill in the art to modify the stent to have the optimal radial force and axial force values needed to achieve the desired results and suit the implantation site. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-7 is/are rejected under 35 U.S.C. 103 as being unpatentable over Grandfield et al. (Pub. No.: US 2017/0303944 A1; hereinafter “Grandfield”) in view of Sirhan et al. (Pub. No. US 2017/0290686 A1; hereinafter “Sirhan”). Grandfield teaches the following regarding claim 1: a stent formed in a tubular shape by braiding one or more wire rods (e.g., Figs. 1B, 13B-13C, 50), wherein when a radial force (N/mm) is denoted as RF (paras. 0113, 0220) and an axial force (N) is denoted as AF (para. 0157), the RF ranges from 0.02 N/mm to 0.04 N/mm (paras. 0113, 0220). Regarding claims 1 and 3, Grandfield teaches the limitations of the claimed invention, as described above. However, it is silent as to the value of the stent’s axial force, and it does not explicitly recite a RF/AF, which is a value obtained by dividing the RF by the AF, being 0.14 mm-1 or more. Sirhan teaches that it is well known in the art that the structural features of a stent are modified or controlled in order to provide the stent with the desired mechanical characteristics needed to best suit the implantation site (paras. 0050-0060, 0074, 0112-0114, 0193-0199, 0253-0256). It has been held that the optimization of parameters is a routine practice that would be obvious for a person of ordinary skill in the art to employ. It would have been customary for one of ordinary skill to determine the optimal radial force and axial force needed to achieve the desired results and suit the implantation site. Thus, absent some demonstration of unexpected results from the claimed parameters, the optimization of the radial force and the axial force, would have been obvious at the time of applicant's invention in view of the teachings of Grandfield and Sirhan. It is well-established that merely selecting proportions and ranges is not patentable absent a showing of criticality. In re Becket, 33 USPQ 33; In re Russell, 169 USPQ 426. Regarding claim 2, Grandfield teaches a shortening of the stent (paras. 0146-0147). However, it does not specify the percentage of shortening that has occurred. The optimization of parameters is a routine practice that would be obvious for a person of ordinary skill in the art to employ. It would have been customary for one of ordinary skill to determine the optimal final stent length needed to achieve the desired results and suit the implantation site. Thus, absent some demonstration of unexpected results from the claimed parameters, the optimization of the shortening percentage, would have been obvious at the time of applicant's invention in view of the teachings of Grandfield and Sirhan. It is well-established that merely selecting proportions and ranges is not patentable absent a showing of criticality. In re Becket, 33 USPQ 33; In re Russell, 169 USPQ 426. Grandfield teaches the following regarding claim 4: the stent according to claim 1 made of a structure formed of the wire rod (e.g., Figs. 1B, 13B-13C, 48A-50), the structure including, along an axial direction, a plurality of circumferential units (strut cells) in which a plurality of meshes is arrayed along a circumferential direction (Figs. 1B, 13B-13C, 48A-50) and including a bent part (e.g., 495, 860, bends in the struts) of one of adjacent circumferential units is coupled to a bent part or a wire rod intersecting part of the other of adjacent circumferential units (Figs. 48A-50). Regarding claims 5 and 7, Grandfield teaches that the wire rod forming the structure has a diameter of from 0.1 mm to 0.5 mm (paras. 0281). However, it does not specify the number of coupling points per unit area of the bent part of the one of adjacent circumferential units and the bent part or the wire rod intersecting part of the other of adjacent circumferential units. The optimization of parameters is a routine practice that would be obvious for a person of ordinary skill in the art to employ. It would have been customary for one of ordinary skill to determine the optimal number of coupling points of the stent elements needed to achieve the desired results and provide the stent with the appropriate mechanical strength and density. Thus, absent some demonstration of unexpected results from the claimed parameters, the optimization of the number of coupling points of the stent elements, would have been obvious at the time of applicant's invention in view of the teachings of Grandfield and Sirhan. It is well-established that merely selecting proportions and ranges is not patentable absent a showing of criticality. In re Becket, 33 USPQ 33; In re Russell, 169 USPQ 426. Grandfield teaches the following regarding claim 6: the stent according to claim 1 made of: a first mesh structure (struts of element 480) formed of a first wire rod (Figs. 47A-50), the first mesh structure including, along an axial direction, a plurality of circumferential units (e.g., cells formed by struts) in which a plurality of meshes is arrayed along a circumferential direction (Figs. 47A-50); and a second mesh structure (495) formed of a second wire rod (Fig. 50), the second mesh structure including, along the axial direction, a plurality of circumferential units (cells formed by 495) in which a plurality of meshes is arrayed along the circumferential direction and braided with the first mesh structure (Fig. 50), wherein in the first mesh structure, a bent part (bent portions of struts) of one of adjacent circumferential units is coupled to a bent part or a wire rod intersecting part of the other of adjacent circumferential units (Figs. 47A-50), and in the second mesh structure, a bent part (distal-most bent portion of element 495) of one of adjacent circumferential units is coupled to none of a bent part and a wire rod intersecting part of the other of adjacent circumferential units (Fig. 50). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Hu whose telephone number is (571) 272-6652. The examiner can normally be reached on Monday-Friday (9:00 am-5:30 pm EST). If attempts to reach the examiner by telephone are unsuccessful, please contact the examiner’s supervisor, Jerrah Edwards, at (408) 918-7557. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANN HU/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Aug 01, 2023
Application Filed
Jan 22, 2026
Non-Final Rejection mailed — §103
Apr 20, 2026
Response Filed
Jul 01, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12661241
DEVICE FOR SHAPING AND CUTTING A BONE GRAFT
3y 6m to grant Granted Jun 23, 2026
Patent 12653663
Fixation Member With Separate Eyelet And Methods Of Use Thereof
2y 8m to grant Granted Jun 16, 2026
Patent 12648847
SEALING MEMBERS FOR PROSTHETIC HEART VALVE
5y 6m to grant Granted Jun 09, 2026
Patent 12642659
SURGICAL INSTRUMENTS AND METHODS
3y 11m to grant Granted Jun 02, 2026
Patent 12642650
MEDICAL DEVICE FOR TREATING A HEART VALVE INSUFFICIENCY
3y 12m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
68%
Grant Probability
89%
With Interview (+21.3%)
3y 9m (~9m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 941 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month